Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer

---

Ak N., Vatansever S.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, vol.46, no.6, pp.1787-1791, 2021 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 46 Issue: 6
• Publication Date: 2021
• Doi Number: 10.1111/jcpt.13364
• Journal Name: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
• Page Numbers: pp.1787-1791
• Keywords: atezolizumab, immunotherapy, microsatellite instability, ovarian cancer, PD-L1
• Istanbul University Affiliated: Yes

Abstract

What is known and objective: Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death-ligand 1 inhibitor atezolizumab.